罗格列酮对代谢综合征患者腹部脂肪分布的影响及其与脂代谢的关系  

Effects of rosiglitazone on abdominal fat distribution and its relationship with lipid metabolism in metabolic syndrome patients

作　　者：胡勤锦[1] 赵志钢[1] 徐兴森[1] 何洪波[1] 钟健[1] 陈静[1] 倪银星[1] 李英莎[1] 闫振成[1] 祝之明[1] 

机构地区：[1]第三军医大学大坪医院野战外科研究所高血压内分泌科,重庆400042

出　　处：《第三军医大学学报》2010年第18期1995-1997,共3页Journal of Third Military Medical University

基　　金：重庆市自然科学基金(CSTC2007BB5085)~~

摘　　要：目的观察罗格列酮对代谢综合征(metabolic,syndrome,MS)患者腹部脂肪分布的影响及其与糖脂代谢的关系。方法 2004-2007年在我科住院诊断为MS的住院患者88例分为治疗组(n=44)和对照组(n=44),治疗组给药罗格列酮(马来酸罗格列酮4mg,1次/d),对照组不给予任何胰岛素增敏剂。2组患者常规控制血糖、血脂、血压,持续时间为12周。最后检测血糖、血脂、C反应蛋白(C-reactive protein,CRP)、尿微量白蛋白(microalbuminuria,MAU),并采用超声测量腹壁脂肪、腹内脂肪厚度。结果与治疗前比较,2组治疗后血糖、血压均显著降低(P<0.05),但治疗组甘油三酯(TG)显著降低而高密度脂蛋白胆固醇(HDL-c)显著增高(P<0.05,P<0.01),同时CRP、腹内脂肪、MAU水平显著降低[CRP:(4.53±4.13)mg/Lvs(2.94±3.11)mg/L;腹内脂肪厚度:(53.41±17.00)mmvs(45.14±16.94)mm;MAU:(67.79±88.55)mg/24hvs(20.22±26.59)mg/24h,P<0.05,P<0.01)。结论罗格列酮可减少MS腹内脂肪含量,抑制炎症反应,改善脂代谢紊乱,可能与减轻肾损害有关。Objective To observe the effects of rosiglitazone on abdominal fat distribution and its relationship with lipid metabolism in the patients with metabolic syndrome（MS）.Methods Eighty-eight MS patients admitted in our hospital from 2004 to 2007 were randomly and equally divided into rosiglitazone group（4 mg/day）and the control group.During the following-up of 12 weeks,blood pressure,and levels of blood lipid and glucose were controlled routinely in both groups.Blood pressure,blood levels of lipid,glucose,C-reactive protein（CRP）and microalbuminuria（MAU）were measured before and after the intervention.The abdominal wall fat and intra-abdominal fat thickness were measured by ultrasonography.Results Systolic blood pressure（SBP）,diastolic blood pressure（DBP）,fasting blood glucose,and glycohemoglobin level were obviously decreased compared with the baselines in both groups.In rosiglitazone group,the triglyceride level was lower,but HDL-C was increased than that before treatment,and the intra-abdominal fat thickness,C-reactive protein and microalbuminuria level were significantly reduced after the treatment of rosiglitazone（CRP：4.53±4.13 vs 2.94±3.11 mg/L;intraabdominal fat thickness：53.41±17.00 vs 45.14±16.94 mm;MAU：67.79±88.55 vs 20.22±26.59 mg per 24 h,P〈0.05 or P〈0.01）.Conclusion Rosiglitazone reduces the intraabdominal fat,suppresses inflammation and improves metabolic disturbance in MS patients,and all these may be due to its protection for renal impairment.

关 键 词：代谢综合征 腹部脂肪 过氧化酶体增殖体激活受体γ 罗格列酮 

分 类 号：R589.2[医药卫生—内分泌] R977.15[医药卫生—内科学]